A Study of Aleglitazar in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This 6 arm study will assess the efficacy, safety, tolerability and pharmacokinetics of
aleglitazar therapy in patients with Type 2 diabetes. Patients will be randomised to one of 6
treatment arms, to receive one of 4 doses of aleglitazar, Actos as an open-label active
comparator, or placebo. Aleglitazar will be administered starting from a dose of 0.05mg po
daily, and Actos will be administered at a dose of 45mg once daily. The anticipated time on
study treatment is 3-12 months, and the target sample size is 100-500 individuals.